Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $60.33M by Medicaid between Jan 2018 and Dec 2024, across 428 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
RIVERSIDE, CA 92505
RIVERSIDE, CA 92505
33aNPI1306991211assigned 01/24/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$60.33M
24GClaims3,037,703
24DCodes billed428
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#51 of 410
Median peer was paid$6.90M
This provider vs. median8.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 237,498 | $1.08M | |
| 2019 | 411,837 | $4.53M | |
| 2020 | 362,022 | $7.77M | |
| 2021 | 417,113 | $9.85M | |
| 2022 | 520,748 | $11.63M | |
| 2023 | 594,476 | $12.08M | |
| 2024incomplete | 494,009 | $13.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 112,485 | 100,739 | $16.19M |
| 0450 | Emergency room services | 6.6% | 86,519 | 76,827 | $3.95M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 13,974 | 13,464 | $2.52M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.6% | 26,272 | 25,334 | $2.15M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.5% | 7,301 | 6,867 | $2.10M |
| G0378 | Hospital observation service, per hour | 2.8% | 6,192 | 3,710 | $1.70M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 16,095 | 15,410 | $1.52M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.2% | 4,492 | 4,333 | $1.33M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 7,336 | 6,963 | $1.29M |
| 80051 | 1.7% | 165,918 | 140,663 | $1.00M | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 141,261 | 121,846 | $999K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 7,690 | 7,452 | $728K |
416 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 22,562 | $689K |
| 82565 | 1.1% | 182,514 | $675K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 15,599 | $589K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 21,488 | $560K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 9,655 | $539K |
| 84702 | <1% | 37,960 | $539K | |
| 76830 | Ultrasound, transvaginal | <1% | 8,805 | $494K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 17,820 | $471K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 17,806 | $471K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,782 | $470K |
| 84520 | <1% | 132,347 | $469K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,676 | $454K |
| 82947 | <1% | 122,550 | $448K | |
| 84460 | <1% | 107,519 | $439K | |
| 86900 | <1% | 15,357 | $437K | |
| 84484 | <1% | 41,440 | $418K | |
| 71045 | Radiologic examination, chest; single view | <1% | 24,931 | $416K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,874 | $387K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,683 | $367K |
| 84075 | <1% | 76,510 | $354K | |
| 82247 | <1% | 81,611 | $351K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 40,375 | $342K |
| 83690 | <1% | 48,925 | $339K | |
| 86885 | <1% | 9,723 | $331K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 458 | $312K |
| 84450 | <1% | 65,958 | $311K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,034 | $286K |
| 93971 | <1% | 2,780 | $273K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,967 | $271K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 54,399 | $257K |
| 83880 | <1% | 15,026 | $246K | |
| 73630 | <1% | 7,458 | $232K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,504 | $228K |
| 80061 | Lipid panel | <1% | 33,140 | $226K |
| 87040 | <1% | 21,453 | $223K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,932 | $218K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 12,151 | $216K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,121 | $198K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,472 | $196K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,446 | $195K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 807 | $194K |
| 87505 | <1% | 2,626 | $181K | |
| 76801 | <1% | 3,455 | $181K | |
| 85027 | <1% | 60,605 | $178K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,600 | $177K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,630 | $175K |
| 70486 | <1% | 1,648 | $167K | |
| 86901 | <1% | 15,375 | $165K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,990 | $162K |
| 81003 | <1% | 84,611 | $161K | |
| 82077 | <1% | 7,723 | $160K | |
| 83605 | <1% | 14,140 | $159K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 10,652 | $155K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 20,874 | $152K |
| 73610 | <1% | 4,821 | $145K | |
| 73562 | <1% | 4,690 | $138K | |
| 81513 | <1% | 2,072 | $136K | |
| 71250 | <1% | 1,609 | $136K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 885 | $133K |
| 87088 | <1% | 29,630 | $132K | |
| 72100 | <1% | 3,062 | $128K | |
| 73030 | <1% | 4,351 | $126K | |
| 73130 | <1% | 4,112 | $121K | |
| 86780 | <1% | 14,104 | $121K | |
| 93970 | <1% | 723 | $118K | |
| 83735 | <1% | 25,312 | $117K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,796 | $115K |
| 80179 | <1% | 4,914 | $114K | |
| 72141 | <1% | 762 | $113K | |
| 90686 | <1% | 7,871 | $112K | |
| 99499 | <1% | 1,040 | $111K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,058 | $107K |
| 76770 | <1% | 2,193 | $101K | |
| 82310 | <1% | 30,768 | $99K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 45,942 | $99K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,427 | $94K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,004 | $94K |
| 86803 | <1% | 10,098 | $93K | |
| 86923 | <1% | 694 | $90K | |
| 74018 | <1% | 2,742 | $87K | |
| 76536 | <1% | 1,810 | $87K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,235 | $85K |
| 85610 | <1% | 38,121 | $84K | |
| 73110 | <1% | 2,937 | $83K | |
| 76870 | <1% | 1,500 | $82K | |
| 82248 | <1% | 16,218 | $77K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 212 | $77K |
| 82728 | <1% | 10,891 | $74K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,556 | $73K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,158 | $72K |
| 86141 | <1% | 9,665 | $71K | |
| 70491 | <1% | 456 | $68K | |
| 87340 | <1% | 10,586 | $66K | |
| 87481 | <1% | 2,155 | $65K | |
| 70496 | <1% | 498 | $64K | |
| 83970 | <1% | 5,143 | $63K | |
| P9021 | Red blood cells, each unit | <1% | 663 | $63K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,073 | $62K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,010 | $61K |
| 86480 | <1% | 1,601 | $60K | |
| 76881 | <1% | 851 | $57K | |
| 74022 | <1% | 1,388 | $56K | |
| 73080 | <1% | 1,936 | $56K | |
| 82607 | <1% | 7,448 | $55K | |
| 73502 | <1% | 1,928 | $54K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 854 | $51K |
| 80306 | <1% | 4,369 | $48K | |
| 85379 | <1% | 5,367 | $48K | |
| 86003 | <1% | 1,704 | $47K | |
| 77080 | <1% | 2,276 | $44K | |
| 73590 | <1% | 1,708 | $43K | |
| 72040 | <1% | 1,349 | $42K | |
| 83550 | <1% | 10,852 | $42K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 984 | $41K |
| 84439 | <1% | 8,304 | $40K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 632 | $38K |
| 73140 | <1% | 1,491 | $38K | |
| 73090 | <1% | 1,710 | $37K | |
| 70498 | <1% | 420 | $37K | |
| 84403 | <1% | 2,515 | $37K | |
| 82805 | <1% | 944 | $33K | |
| 72131 | <1% | 322 | $31K | |
| 86762 | <1% | 3,464 | $31K | |
| 85730 | <1% | 6,935 | $31K | |
| 83540 | <1% | 11,095 | $31K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,499 | $30K |
| 82746 | <1% | 4,221 | $29K | |
| 86787 | <1% | 3,580 | $29K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 849 | $29K |
| 82570 | <1% | 10,689 | $29K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,003 | $29K |
| 82550 | <1% | 4,441 | $28K | |
| 74174 | <1% | 134 | $27K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,038 | $27K |
| 82043 | <1% | 11,917 | $27K | |
| 96367 | <1% | 773 | $27K | |
| 80076 | <1% | 4,412 | $27K | |
| 84146 | <1% | 2,105 | $27K | |
| 84100 | <1% | 13,529 | $27K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 712 | $26K |
| 87081 | <1% | 4,538 | $26K | |
| 76641 | <1% | 342 | $26K | |
| 87186 | <1% | 2,981 | $25K | |
| 87210 | <1% | 8,417 | $25K | |
| 83001 | <1% | 2,046 | $25K | |
| 83655 | <1% | 5,137 | $25K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 307 | $24K |
| J3490 | Unclassified drugs | <1% | 6,590 | $24K |
| 82040 | <1% | 11,580 | $24K | |
| 93017 | <1% | 187 | $23K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12,850 | $22K |
| 0637 | <1% | 63,912 | $21K | |
| 87449 | <1% | 3,344 | $20K | |
| 83520 | <1% | 3,424 | $20K | |
| 86317 | <1% | 2,289 | $19K | |
| 71101 | <1% | 378 | $19K | |
| 90674 | <1% | 764 | $18K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,230 | $18K |
| 84156 | <1% | 9,736 | $18K | |
| 88173 | <1% | 408 | $18K | |
| 77066 | Tomosynthesis, mammo | <1% | 173 | $18K |
| 82950 | <1% | 6,259 | $18K | |
| 83615 | <1% | 5,024 | $18K | |
| 82670 | <1% | 852 | $18K | |
| 82105 | <1% | 2,114 | $17K | |
| Z7502 | <1% | 690 | $17K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,364 | $17K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 266 | $17K |
| 72070 | <1% | 307 | $17K | |
| 87536 | <1% | 525 | $16K | |
| 73700 | <1% | 167 | $16K | |
| 85652 | <1% | 10,647 | $16K | |
| 86665 | <1% | 1,569 | $16K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,078 | $16K |
| 82951 | <1% | 1,851 | $16K | |
| 84153 | <1% | 2,705 | $16K | |
| 74220 | <1% | 189 | $15K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,400 | $15K |
| 0710 | <1% | 1,055 | $15K | |
| 73060 | <1% | 676 | $15K | |
| 83002 | <1% | 1,140 | $14K | |
| 73560 | <1% | 692 | $14K | |
| 83021 | <1% | 1,551 | $14K | |
| 88342 | <1% | 338 | $14K | |
| 86704 | <1% | 2,121 | $14K | |
| 72081 | <1% | 402 | $13K | |
| 73564 | <1% | 212 | $13K | |
| 72050 | <1% | 201 | $13K | |
| 74178 | <1% | 58 | $13K | |
| 83721 | <1% | 2,467 | $13K | |
| 73552 | <1% | 603 | $13K | |
| 87205 | <1% | 3,960 | $13K | |
| 87497 | <1% | 524 | $12K | |
| 12001 | <1% | 1,002 | $12K | |
| 74170 | <1% | 86 | $12K | |
| 86765 | <1% | 1,324 | $12K | |
| 84132 | <1% | 5,411 | $12K | |
| 86038 | <1% | 1,939 | $12K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,411 | $12K |
| 90715 | <1% | 416 | $12K | |
| J1815 | Injection, insulin, per 5 units | <1% | 5,791 | $12K |
| 73660 | <1% | 358 | $11K | |
| 82140 | <1% | 978 | $11K | |
| 84480 | <1% | 1,670 | $11K | |
| 87324 | <1% | 1,944 | $11K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,879 | $11K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 488 | $11K |
| 82784 | <1% | 1,523 | $11K | |
| 82962 | <1% | 3,007 | $11K | |
| 83993 | <1% | 702 | $10K | |
| 87631 | <1% | 315 | $10K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 259 | $10K |
| 82627 | <1% | 587 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 24,673 | $10K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,521 | $9K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,347 | $9K |
| 84550 | <1% | 4,461 | $9K | |
| 83718 | <1% | 2,212 | $9K | |
| 80164 | <1% | 851 | $8K | |
| 73221 | <1% | 66 | $8K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 914 | $8K |
| 86225 | <1% | 980 | $8K | |
| 97161 | <1% | 658 | $8K | |
| 93880 | <1% | 70 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,801 | $8K |
| 74240 | <1% | 66 | $7K | |
| 84134 | <1% | 1,308 | $7K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 155 | $7K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 68 | $7K |
| 80197 | <1% | 1,343 | $7K | |
| 86664 | <1% | 786 | $7K | |
| 84295 | <1% | 2,842 | $7K | |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 135 | $7K |
| 82465 | <1% | 2,930 | $6K | |
| 77072 | <1% | 68 | $6K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 1,249 | $6K |
| 73100 | <1% | 185 | $6K | |
| 72146 | <1% | 38 | $6K | |
| 86364 | <1% | 556 | $6K | |
| 73522 | <1% | 107 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,796 | $6K |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 681 | $6K |
| 72170 | <1% | 250 | $5K | |
| 88341 | <1% | 122 | $5K | |
| 84165 | <1% | 1,494 | $5K | |
| 74183 | <1% | 27 | $5K | |
| 82952 | <1% | 1,836 | $5K | |
| 74181 | <1% | 25 | $5K | |
| 80321 | <1% | 120 | $5K | |
| 81015 | <1% | 2,153 | $5K | |
| 84270 | <1% | 254 | $5K | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,439 | $5K |
| 87070 | <1% | 741 | $5K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,644 | $4K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,207 | $4K |
| 90656 | <1% | 522 | $4K | |
| 12011 | <1% | 255 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,894 | $4K |
| 0258 | <1% | 1,552 | $4K | |
| 10060 | <1% | 284 | $4K | |
| 83525 | <1% | 403 | $4K | |
| 86431 | <1% | 1,157 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,344 | $4K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 532 | $4K |
| 82533 | <1% | 328 | $4K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,165 | $4K |
| 86360 | <1% | 374 | $4K | |
| 76380 | <1% | 72 | $3K | |
| 86769 | <1% | 202 | $3K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 740 | $3K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 282 | $3K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,381 | $3K |
| 85046 | <1% | 1,138 | $3K | |
| 82150 | <1% | 894 | $3K | |
| 90662 | <1% | 346 | $3K | |
| 70544 | <1% | 13 | $3K | |
| 84155 | <1% | 1,095 | $3K | |
| 29125 | <1% | 518 | $3K | |
| 86709 | <1% | 370 | $3K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 945 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,002 | $3K |
| 0250 | <1% | 8,054 | $3K | |
| 86359 | <1% | 374 | $3K | |
| 87149 | <1% | 312 | $3K | |
| 82977 | <1% | 497 | $3K | |
| 86308 | <1% | 700 | $3K | |
| 86735 | <1% | 396 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,374 | $2K |
| 85014 | <1% | 2,788 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 12 | $2K |
| 81329 | <1% | 24 | $2K | |
| 86300 | <1% | 215 | $2K | |
| 0255 | <1% | 466 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,134 | $2K |
| 82378 | <1% | 223 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,026 | $2K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 28 | $2K |
| 85018 | <1% | 1,736 | $2K | |
| 90688 | <1% | 169 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,479 | $2K |
| 74019 | <1% | 108 | $2K | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 1,476 | $2K |
| 29515 | <1% | 364 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 954 | $2K |
| 86677 | <1% | 882 | $2K | |
| 80359 | <1% | 31 | $2K | |
| 86870 | <1% | 14 | $2K | |
| 84478 | <1% | 412 | $2K | |
| 80324 | <1% | 32 | $2K | |
| 99199 | Unlisted special service, procedure or report | <1% | 140 | $2K |
| 82272 | <1% | 496 | $1K | |
| 86696 | <1% | 117 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 17 | $1K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,483 | $1K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,291 | $1K |
| 70360 | <1% | 52 | $1K | |
| 86301 | <1% | 123 | $1K | |
| 84145 | <1% | 127 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,178 | $1K |
| 87807 | <1% | 251 | $1K | |
| 86140 | <1% | 1,476 | $1K | |
| 86160 | <1% | 192 | $1K | |
| 86635 | <1% | 157 | $1K | |
| 82390 | <1% | 170 | $1K | |
| 86708 | <1% | 158 | $1K | |
| 73120 | <1% | 40 | $1K | |
| 85045 | <1% | 440 | $1K | |
| 72082 | <1% | 12 | $1K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 33 | $1K |
| 86695 | <1% | 117 | $1K | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 108 | $1K |
| 12002 | <1% | 100 | $1K | |
| 82330 | <1% | 146 | $978.40 | |
| 82677 | <1% | 39 | $963.00 | |
| 87522 | Neg quan hep c or qual rna | <1% | 87 | $962.52 |
| 88312 | <1% | 65 | $929.41 | |
| 84425 | <1% | 76 | $911.00 | |
| 88304 | <1% | 313 | $899.84 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 445 | $886.75 |
| 99217 | <1% | 145 | $842.70 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 473 | $836.06 |
| 86880 | <1% | 62 | $825.43 | |
| 89051 | <1% | 182 | $808.50 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,550 | $770.56 |
| 83930 | <1% | 208 | $713.98 | |
| 86256 | <1% | 52 | $662.62 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 313 | $638.73 |
| 82103 | <1% | 66 | $619.06 | |
| 86336 | <1% | 39 | $580.00 | |
| 86376 | <1% | 171 | $559.35 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,592 | $551.02 |
| 84163 | <1% | 88 | $542.86 | |
| 86334 | <1% | 67 | $539.74 | |
| 80178 | <1% | 165 | $518.52 | |
| 73070 | <1% | 16 | $499.42 | |
| 92610 | <1% | 70 | $483.79 | |
| 80185 | <1% | 45 | $441.29 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 51 | $422.55 |
| 72072 | <1% | 14 | $382.56 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 487 | $320.07 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 517 | $307.47 |
| 83935 | <1% | 110 | $299.90 | |
| 85246 | <1% | 13 | $275.00 | |
| 85245 | <1% | 13 | $255.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 159 | $227.81 |
| 82024 | <1% | 14 | $212.66 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 866 | $210.62 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 146 | $207.96 |
| 82705 | <1% | 52 | $204.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 232 | $202.52 |
| 86304 | <1% | 12 | $169.00 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 43 | $159.43 |
| 0370 | <1% | 1,104 | $146.17 | |
| 85384 | <1% | 25 | $140.04 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 120 | $127.90 |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | <1% | 34 | $122.45 |
| 85613 | <1% | 27 | $115.00 | |
| C1769 | Guide wire | <1% | 161 | $106.95 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 13 | $104.64 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 53 | $98.92 |
| 29130 | <1% | 14 | $78.00 | |
| 87185 | <1% | 53 | $64.41 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 114 | $40.05 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 29 | $38.22 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 84 | $34.36 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 52 | $30.36 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 18 | $24.78 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 12 | $23.60 |
| 90749 | <1% | 26 | $23.17 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 19 | $20.64 |
| 87045 | <1% | 31 | $17.80 | |
| 82945 | <1% | 12 | $13.16 | |
| 88307 | <1% | 31 | $12.57 | |
| 87046 | <1% | 33 | $7.83 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $7.47 |
| 3052F | <1% | 265 | $0.01 | |
| 3046F | 0% | 450 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 25 | $0.00 |
| 3051F | 0% | 424 | $0.00 | |
| 0272 | 0% | 257 | $0.00 | |
| 87338 | 0% | 13 | $0.00 | |
| 3078F | 0% | 182 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 17 | $0.00 |
| 82274 | 0% | 13 | $0.00 | |
| 0320 | 0% | 16 | $0.00 | |
| J2280 | Injection, moxifloxacin, 100 mg | 0% | 122 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 139 | $0.00 |
| 3044F | 0% | 3,813 | $0.00 | |
| 3074F | 0% | 184 | $0.00 | |
| 0306 | 0% | 22 | $0.00 | |
| 90839 | 0% | 13 | $0.00 | |
| 80320 | 0% | 27 | $0.00 | |
| 0301 | 0% | 119 | $0.00 | |
| 80156 | 0% | 17 | $0.00 | |
| 99285 | Emergency room visit (most serious) | 0% | 12 | $0.00 |
| 0305 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLETT, VITA (EXECUTIVE DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Hospitals | Moreno Valley, CA | $26.26M |
| Kaiser Foundation Hospitals | Moreno Valley, CA | $115K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.